BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Upstream Bio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Upstream Bio's drugs run\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06966479-1535@assetmemo.bio
DTSTAMP:20261121T005357Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:verekitug: Phase 2 readout est. (NCT06966479)
DESCRIPTION:verekitug\, phase 2\, Asthma.\nStudy: A Long-Term Safety and Ef
 ficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asth
 ma (VALOUR)\nEstimated primary completion: September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/verekitug#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06966479
URL:https://assetmemo.bio/drug/verekitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06981078-1535@assetmemo.bio
DTSTAMP:20261121T005357Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:verekitug: Phase 2 readout est. (NCT06981078)
DESCRIPTION:verekitug\, phase 2\, Chronic Obstructive Pulmonary Disease.\nS
 tudy: A Study to Assess the Efficacy and Safety of Verekitug in Participan
 ts With COPD\nEstimated primary completion: October 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/verekitug#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06981078
URL:https://assetmemo.bio/drug/verekitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
